Wed, Sep 17, 2014, 12:32 AM EDT - U.S. Markets open in 8 hrs 58 mins

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • inetquirk inetquirk Dec 1, 2012 1:00 PM Flag

    Exceptional review

    Trading volume Friday November 30, 2012 increase sparks review of Sunesis Pharmaceuticals, Inc.

    Trading on October 5, 2012 reveals a HOD of $6.85 that has technically retraced forming a solid base (floor) at just under $5 a share. Money flow indicators since retracing, point towards an influx into rather than out of SNSS stock.

    The catalyst: Vosaroxin a late stage trials for treating an aggressive cancer of the blood. Vosaroxin is Sunesis's most advanced currently experimental drug.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A favorable outlook was taken when upsizing of the current trial took place as it was based on efficacy data trending in the "promising zone" and significantly improves the trials odds of success.

      Estimates are that vosaroxin can likely achieve peak annual sales of $700 million. Physicians are noting that vosaroxin likely will extend beyond the refractory AML setting such as first line settings when patients are at high risk of relapse or have cardiovascular issues.

      Dan Swisher - Cheif Executive Officer for Sunesis Pharmaceuticals, Inc. said: SNS has the cash through 2014, which is beyond several key milestones. Why is this important? (extremely low chance of dilution without significant share appreciation)

      • 5 Replies to inetquirk
      • RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

      • Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an "Outperform" rating on Sunesis shares and raised his price target to $10 a share.

      • Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an "Outperform" rating on Sunesis shares and raised his price target to $10 a share.

        RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

      • Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an "Outperform" rating on Sunesis shares and raised his price target to $10 a share.

        RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

        This review establishes an opinion of: MARKET OUTPERFORM price target $20

      • Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an "Outperform" rating on Sunesis shares and raised his price target to $10 a share.

        RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

        This review establishes an opinion of: MARKET OUTPERFORM price target $20

        Investors will probably agree with this review using their due diligence/fact checking.

        Respectfully,
        Inetquirk

 
SNSS
7.000.00(0.00%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.